OncoRNA: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
OncoRNA
Largest movements
- Cash +€4,397
up €4,397 (+29.3%), from €15,028 to €19,424
mainly Other debts (+€25,000) and Receivables within one year (+€959)
- Receivables within one year -€959
down €959 (-61.1%), from €1,569 to €610
of which Other amounts receivable: -€1,126
- Other debts +€25,000
up €25,000 (+93.0%), from €26,880 to €51,880
- Profit (loss) carried forward -€15,560
down €15,560 (-20.0%), from -€77,786 to -€93,346
- Trade debts -€6,002
no longer reported in 2025 (was €6,002)
- Gross operating margin +€21,069
up €21,069 (+58.0%), from -€36,306 to -€15,237
- Staff costs -€1,578
down €1,578, from €1,238 to -€340
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €16,596 | €20,034 | +€3,438 | +20.7% |
| Current assets | 29/58 | €16,596 | €20,034 | +€3,438 | +20.7% |
| Amounts receivable within one year | 40/41 | €1,569 | €610 | -€959 | -61.1% |
| Trade receivables | 40 | - | €167 | +€167 | |
| Other amounts receivable | 41 | €1,569 | €443 | -€1,126 | -71.8% |
| Cash at bank and in hand | 54/58 | €15,028 | €19,424 | +€4,397 | +29.3% |
| Total equity and liabilities | 10/49 | €16,596 | €20,034 | +€3,438 | +20.7% |
| Equity | 10/15 | -€16,286 | -€31,846 | -€15,560 | -95.5% |
| Contributions | 10/11 | €61,500 | €61,500 | = | 0.0% |
| Capital | 10 | €61,500 | €61,500 | = | 0.0% |
| Issued capital | 100 | €61,500 | €61,500 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€77,786 | -€93,346 | -€15,560 | -20.0% |
| Amounts payable | 17/49 | €32,882 | €51,880 | +€18,998 | +57.8% |
| Amounts payable within one year | 42/48 | €32,882 | €51,880 | +€18,998 | +57.8% |
| Trade debts | 44 | €6,002 | - | -€6,002 | |
| Suppliers | 440/4 | €6,002 | - | -€6,002 | |
| Other amounts payable | 47/48 | €26,880 | €51,880 | +€25,000 | +93.0% |
| Remuneration, social security and pensions | 62 | €1,238 | -€340 | -€1,578 | |
| Other operating charges | 640/8 | €271 | €244 | -€27 | -10.0% |
| Gross operating margin | 9900 | -€36,306 | -€15,237 | +€21,069 | +58.0% |
| Operating profit (loss) | 9901 | -€37,815 | -€15,141 | +€22,674 | +60.0% |
| Financial charges | 65/66B | €454 | €420 | -€34 | -7.5% |
| Recurring financial charges | 65 | €454 | €420 | -€34 | -7.5% |
| Profit (loss) for the period before taxes | 9903 | -€38,269 | -€15,560 | +€22,708 | +59.3% |
| Profit (loss) for the period | 9904 | -€38,269 | -€15,560 | +€22,708 | +59.3% |
| Profit (loss) for the period to be appropriated | 9905 | -€38,269 | -€15,560 | +€22,708 | +59.3% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 29 September 2026 via checked.be.